Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of TJ107 plus pembrolizumab in advanced or metastatic solid tumors
CTR20212803Phase 2Active
- Sponsor
- I-Mab
- Start
- Jan 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of efineptakin alpha and pembrolizumab in Nonhematologic neoplasms, triple-negative breast cancer (TNBC) and head and neck squamous cell carcinoma (HNSCC), sponsored by I-Mab. Primary endpoints: Safety and tolerability and Objective response rate. Started Jan 2022; status: active.
02
Drugs
efineptakin alphapembrolizumab
03
Conditions
Nonhematologic neoplasmstriple-negative breast cancer (TNBC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20212803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212803.